Interview with Michael Azrak, Managing Director, MSD South Africa
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Address: 117 – 16th Road, Halfway House, Midrand 1685,South Africa
Tel: +27 11 655 3000
From developing new therapies that treat and prevent disease to helping people in need, we’re committed to improving health and well-being around the world.
We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce.
At MSD, we’re applying our global reach and strength in scientific research to do more of what we’re passionate about: working to ensure a healthier future for all – one person at a time.
Our products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women’s health. And we focus our research on conditions that affect millions of people around the world – diseases like Alzheimer’s, diabetes and cancer – while building strengths in new areas like biologics.
While we work to develop innovative therapies, we also work hard to make sure they’re affordable. That’s why we offer assistance and discount programs to help make our medicines accessible to those who need them.
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Kelly du Plessis is CEO & Founder of Rare Diseases South Africa, a registered NPO born out of necessity when her oldest child was diagnosed with Pompe disease at 11…
Trailing behind South Africa’s pharmaceutical market in both value and growth, the nation’s medical device industry has long enjoyed minimal barriers to entry and easy market access. But, with imminent…
The traditional model of healthcare has generally been limited to treatment in health facilities. But, when it comes to effectively treating more private and deeply personal health conditions, especially in…
Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However,…
While South Africa faces a distinct set of challenges in effectively managing its healthcare sector, the ecosystem for innovation, particularly in the world of biotechnology remains fruitful. Bioentrepreneur Nick Duneas…
Hersol prides itself on producing high-quality products and is today one of the leading Pharmaceutical Contract Manufacturing Companies (CMOs) within the South African Market. The managing director discusses the development…
Albert Denoon (AB) and Jeff Hampton (JH) illustrate how the Crossroads and Campbell Institutes, two non-profit organizations funded by Baroque Medical, are well positioned to address South Africa’s current gaps…
The general manager of Bard SA, Charl De Klerk, illustrates the company’s growth ambitions within South Africa and Sub-Saharan Africa, while also depicting how Bard has adapted its therapeutic portfolio…
The head of KPMG’s life science division in Africa, Joubert Krugel, discusses the current state of South Africa’s healthcare system, the imminent trends taking place, and how the business community…
Marius Fourie highlights implications of the recent merger between the company’s two subsidiaries and the unparalleled levels of value and service the consolidated organization will offer. He also illustrates the affiliate’s strategies…
Tania Zulu Holt, Associate Principal at McKinsey & Company elaborates on the current pressures on the South African healthcare system, discusses the importance of innovation and emphasizes the need for…
Abbvie GM for South Africa Christo Kruger highlights the various types of projects that the Public Health Enhancement Fund (PHEF) is pursuing to help alleviate the country’s currently overburdened healthcare…
See our Cookie Privacy Policy Here
